{"id":"W4281986919","doi":"10.1200/jco.2022.40.16_suppl.7549","title":"Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Progressive disease; Progression-free survival; Bruton's tyrosine kinase; Phases of clinical research; Tolerability; Nausea; Ibrutinib; Oncology; Clinical trial; Surgery; Adverse effect; Chronic lymphocytic leukemia; Chemotherapy; Leukemia; Tyrosine kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01048047,0.0002278779,0.002426607,0.0004054387,0.00007909611,0.00001422221,0.0008819035,0.0003292918,0.0003554129],"category_scores_gemma":[0.009345992,0.0001661774,0.0002559336,0.0005651561,0.0004370006,0.0002360674,0.0007084762,0.001797848,0.00001154376],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.008532936,"about_ca_system_score_gemma":0.03065238,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003124359,"about_ca_topic_score_gemma":0.00004901687,"domain_scores_codex":[0.9905964,0.001851048,0.004955547,0.0004379166,0.001630332,0.0005287663],"domain_scores_gemma":[0.9894992,0.004736067,0.003832648,0.0005666466,0.0007826117,0.0005828168],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7974495,0.0763676,0.00411243,0.00004981658,0.0003839914,0.00233016,0.0001857041,0.00001762609,0.00004347173,0.00001875549,0.007829781,0.1112112],"study_design_scores_gemma":[0.7603127,0.1511667,0.01303398,0.0001646901,0.0002059781,0.00016889,0.0001697796,0.0006962142,0.00002441953,0.00001613041,0.07391723,0.0001232527],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931844,0.0001920663,0.00001813432,0.001897423,0.001200801,0.001414639,0.00005275454,0.000006777456,0.002032945],"genre_scores_gemma":[0.9947406,0.0001620466,0.002580212,0.001073779,0.0004146681,0.00003334821,0.00003054217,0.00004079673,0.00092402],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1110879,"threshold_uncertainty_score":0.9989987,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1423006420353606,"score_gpt":0.4852941723705371,"score_spread":0.3429935303351764,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}